Seres Therapeutics (MCRB)
(Real Time Quote from BATS)
$0.92 USD
0.00 (0.37%)
Updated May 28, 2024 01:06 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Earnings News For MCRB
-
Seres Therapeutics: Q1 Earnings Snapshot
-
Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
-
Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
-
Seres Therapeutics: Q3 Earnings Snapshot
-
Seres Therapeutics Reports Third Quarter 2023 Financial Results Including VOWST? Net Sales of $7.6 Million
-
Seres Therapeutics (MCRB) Misses Q2 Earnings Estimates
-
Seres Therapeutics: Q2 Earnings Snapshot
-
Seres Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
-
Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates
-
Seres Therapeutics: Q1 Earnings Snapshot
-
Seres Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
-
Seres Therapeutics (MCRB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
-
Seres Therapeutics (MCRB) Reports Q4 Loss, Misses Revenue Estimates
-
Seres Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
-
Seres Therapeutics (MCRB) Reports Q3 Loss, Lags Revenue Estimates
-
Seres Therapeutics: Q3 Earnings Snapshot
-
Seres Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
-
Seres Therapeutics (MCRB) Reports Q2 Loss, Lags Revenue Estimates
-
Seres Therapeutics: Q2 Earnings Snapshot
-
Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
-
Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates
-
Seres Therapeutics (MCRB) Reports Q4 Loss, Lags Revenue Estimates
-
Seres Therapeutics (MCRB) Q3 Earnings and Revenues Beat Estimates
-
Analysts Estimate Seres Therapeutics (MCRB) to Report a Decline in Earnings: What to Look Out for
-
Seres Therapeutics (MCRB) Reports Q2 Loss, Tops Revenue Estimates